We are live on ! Find out more
AXN

Aoxing Pharmaceutical
AXN

Delisted

AXN was delisted on the 16th of October, 2017.

2 hedge funds and large institutions have $17K invested in Aoxing Pharmaceutical in 2013 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more capital inflows, than outflows

Capital inflows: $13.1K | Capital outflows: $9K

0.03% more ownership

Funds ownership: 0.11% → 0.13% (+0.03%)

33% less funds holding

Funds holding: 3 → 2 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$13.1K

Top Sellers

Rank Fund Capital Flow
1
Cetera Advisors
Cetera Advisors
Colorado
-$7K
2
UBS
UBS
Switzerland
-$2K

AXN Hedge Fund Activity: Q3 2013 in Review

2 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical (AXN) for Q3 2013, worth a combined $17K — up 42% from $12K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of AXN and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $13.1K. The largest seller was Cetera Advisors, exiting entirely with an estimated $7K sold.

  • 2 institutional investors held Aoxing Pharmaceutical (AXN) as of Q3 2013, down from 3 in Q2 2013.
  • Funds reported $17K of Aoxing Pharmaceutical stock for Q3 2013, up 42% quarter-over-quarter.
  • 1 fund opened new Aoxing Pharmaceutical positions in Q3 2013 and 2 closed out, a net change of -1 holder.
  • The largest Aoxing Pharmaceutical buyer in Q3 2013 was Citadel Advisors, an estimated $13.1K added.
  • The largest Aoxing Pharmaceutical seller in Q3 2013 was Cetera Advisors, an estimated $7K sold.

Based on aggregated 13F filings for Q3 2013.